OncoMatch/Clinical Trials/NCT05008809
Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)
Is NCT05008809 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including mFOLFOX6 and mFOLFOXIRI for colorectal cancer.
Treatment: mFOLFOX6 · mFOLFOXIRI · FOLFIRI · CAPOX — This is an open-label, randomized, controlled, multicenter, phase III study with two parallel arms. Patients with metastatic colorectal cancer after definite interventional therapy of all lesions are randomized in a 2:1 fashion (favoring active therapy) to investigate the efficacy, patient reported quality of life and safety of mFOLFOXIRI/mFOLFOX-6 as additive treatment (Arm A) versus active follow-up/surveillance (Arm B).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Colorectal Cancer
Disease stage
Metastatic disease required
Resected (R0 or R1) and/or effectively treated metastases (all techniques allowed) of colorectal cancer within 3-10 weeks before randomization ... AND resected primary tumor (synchronous or metachronous)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.5 x 10^9/L (1500/µL); Hemoglobin ≥ 80 g/L (8 g/dL); Platelet count ≥ 100 x10^9/L (100000/µL) without transfusion
Kidney function
Calculated GFR ≥ 50 mL/min or serum creatinine ≤ 1.5 x ULN
Liver function
Total serum bilirubin of ≤ 1.5 x ULN; AST/GOT ≤ 3.0 × ULN
Adequate bone marrow, hepatic and renal organ function, defined by the following laboratory test results: ... [see above]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05008809 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages